Free Trial
NASDAQ:OLMA

Olema Pharmaceuticals Q1 2025 Earnings Report

Olema Pharmaceuticals logo
$4.64 -0.08 (-1.69%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$4.63 -0.01 (-0.22%)
As of 08/8/2025 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Olema Pharmaceuticals EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.49
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Olema Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Olema Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Olema Pharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Friday, August 15, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Olema Pharmaceuticals Earnings Headlines

Olema Pharmaceuticals (OLMA) to Release Earnings on Tuesday
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
See More Olema Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Olema Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Olema Pharmaceuticals and other key companies, straight to your email.

About Olema Pharmaceuticals

Olema Pharmaceuticals (NASDAQ:OLMA), a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

View Olema Pharmaceuticals Profile

More Earnings Resources from MarketBeat